Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Author: Avi Kapoor | September 09, 2024 06:08am

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) rose sharply in today's pre-market trading after the company said Ivonescimab Monotherapy reduced the risk of disease progression or death by 49% compared to pembrolizumab monotherapy in first-line treatment of patients with PD-L1 positive advanced NSCLC in China.

Summit Therapeutics shares jumped 38.8% to $16.99 in the pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

  • Intelligent Bio Solutions Inc.  (NASDAQ:INBS) gained 72.7% to $2.73 in pre-market trading after jumping over 20% on Friday.
  • Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) rose 48.8% to $0.2120 in today's pre-market trading after dipping 10% on Friday.
  • Nuburu, Inc. (NYSE:BURU) gained 48% to $0.7650 in the pre-market trading session after falling 16% on Friday.
  • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) gained 30.6% to $1.14 in pre-market trading after dipping over 25% on Friday.
  • Meiwu Technology Co Ltd (NASDAQ:MWG) gained 13.5% to $0.4515 in pre-market trading after declining 5% on Friday.
  • Versus Systems Inc. (NASDAQ:VS) shares gained 12.3% to $1.64 in pre-market trading after gaining 7% on Friday.
  • Femasys Inc. (NASDAQ:FEMY) gained 9.4% to $1.17 in pre-market trading.
  • Savara Inc. (NASDAQ:SVRA) gained 9.3% to $4.83 in pre-market trading. Savara unveiled Phase 3 IMPALA-2 trial data on molgramostim for autoimmune pulmonary alveolar proteinosis at ERS Congress 2024.
  • MSP Recovery, Inc. (NASDAQ:LIFW) rose 8.4% to $0.1788 in pre-market trading. LifeWallet secured a key waiver from largest creditor, launching new agreements with health plans and insurers.

Losers

  • Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) fell 21.3% to $8.06 in pre-market trading. Wheeler Real Estate Investment Trust shares jumped 148% on Friday after the company and its subsidiary, Cedar Realty Trust, announced that the United States Court of Appeals for the Fourth Circuit affirmed a 2023 order dismissing a putative class action complaint filed against the company and Cedar by purported holders of Cedar’s preferred stock.
  • Golden Minerals Company (NYSE:AUMN) shares fell 18.2% to $0.2208 in pre-market trading after declining around 10% on Friday.
  • C4 Therapeutics, Inc.. (NASDAQ:CCCC) shares declined 17% to $4.48 in pre-market trading. C4 Therapeutics will reveal preliminary CFT1946 monotherapy Phase 1 clinical data at ESMO Congress 2024.
  • Beneficient (NASDAQ:BENF) shares declined 15.6% to $1.73 in pre-market trading after jumping over 36% on Friday.
  • Eastside Distilling, Inc. (NASDAQ:EAST) fell 14.7% to $1.210 in pre-market trading. Eastside Distilling announced closing of $0.4 million registered direct offering, priced at a premium to market under Nasdaq rules.
  • Biomerica, Inc. (NASDAQ:BMRA) fell 13.3% to $0.3007 in today's pre-market trading after dipping 9% on Friday. Biomerica shares fell around 9% on Friday after the company announced its 10-minute at-home PSA test for early prostate cancer detection was approved by the Saudi FDA.
  • Mullen Automotive, Inc. (NASDAQ:MULN) shares fell 12.2% to $0.1660 in pre-market trading after dipping 12% on Friday. The company announced today that its subsidiary, Bollinger Motors, has partnered with Texas Consulting & Development to provide Bollinger B4 Class 4 trucks.
  • Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares fell 11.1% to $3.84 in pre-market trading after gaining 5% on Friday.
  • Lotus Technology Inc. (NASDAQ:LOT) shares dipped 5.4% to $4.90 in pre-market trading after gaining around 6% on Friday.
  • Merck & Co., Inc. (NYSE:MRK) declined 4.8% to $112.23 in pre-market trading. Daiichi Sankyo and Merck’s Ifinatamab Deruxtecan showed response rates in extensive-stage small cell lung cancer in Phase 2 IDeate-Lung01 trial.

Now Read This:

Posted In: AUMN BENF BMRA BURU CCCC DSY EAST FEMY INBS IVP LIFW LOT MRK MULN MWG SMMT SVRA TNXP VS WHLR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist